The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) is conducted and supported by the NHLBI in collaboration with the AFFIRM Study Investigators. This manuscript was prepared using a limited access dataset obtained from the NHLBI and does not necessarily reflect the opinions or views of the AFFIRM or the NHLBI.
The Effects of Rate and Rhythm Control on Blood Pressure and Antihypertensive Drug Usage in Patients with Atrial Fibrillation and Hypertension Enrolled in the AFFIRM Trial
Article first published online: 29 APR 2010
© 2010 Wiley Periodicals, Inc.
Journal of Cardiovascular Electrophysiology
Volume 21, Issue 10, pages 1094–1098, October 2010
How to Cite
MASOOD, S. O., WASMUND, S. L., AKOUM, N. W., EGGER, M. J., HSIAI, T. and HAMDAN, M. H. (2010), The Effects of Rate and Rhythm Control on Blood Pressure and Antihypertensive Drug Usage in Patients with Atrial Fibrillation and Hypertension Enrolled in the AFFIRM Trial. Journal of Cardiovascular Electrophysiology, 21: 1094–1098. doi: 10.1111/j.1540-8167.2010.01792.x
- Issue published online: 29 APR 2010
- Article first published online: 29 APR 2010
- Manuscript received 9 February 2010; Revised manuscript received 4 March 2010; Accepted for publication 12 March 2010.
- atrial fibrillation;
- AFFIRM study;
- rate control;
- rhythm control
AF and HTN in the AFFIRM trial. Introduction: Atrial fibrillation (AF) has been shown to be associated with activation of the renin–angiotensin–aldosterone system, endothelial dysfunction, and increased sympathetic activity, all of which could lead to hypertension (HTN). While the effects of HTN on AF incidence and arrhythmogenesis have been reported, the long-term effects of AF on blood pressure (BP) remain unknown. We hypothesized that a rate control strategy is associated with an increase in BP and/or antihypertensive drug therapy when compared with a rhythm control strategy in patients with a history of AF and HTN.
Methods and Results: Using the intention to treat method, BP readings and the number of antihypertensive medication categories were analyzed over the first year of follow-up in patients with AF and HTN enrolled in the AFFIRM trial. No clinically significant changes in BP occurred. Medication data were available in 2,876 patients. In the rate control group, 27.8% of patients required a net increase in the number of antihypertensive medications when compared to 18.3% in the rhythm control group (P < 0.001). Furthermore, 27.1% of patients in the rate control group had a net decrease in the number of antihypertensive medications when compared with 41.7% in the rhythm control group (P < 0.001).
Conclusions: Our findings suggest that AF could be contributing to BP elevation in patients with a history of HTN and that a rhythm control strategy might result in a decrease in BP in these patients. This hypothesis however, requires future testing. (J Cardiovasc Electrophysiol, Vol. 21, pp. 1094-1098)